uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

uniQure N.V. (NASDAQ:QURE) has received a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, ten have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $64.4167.

A number of research analysts have recently weighed in on the stock. Mizuho raised their price objective on shares of uniQure from $30.00 to $60.00 and gave the stock an “outperform” rating in a research note on Thursday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, October 8th. Leerink Partners dropped their price target on uniQure from $68.00 to $60.00 and set an “outperform” rating for the company in a research report on Monday, November 10th. Wells Fargo & Company reduced their price objective on uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 12th. Finally, UBS Group set a $95.00 price objective on uniQure in a research report on Thursday, September 25th.

Insiders Place Their Bets

In related news, CFO Christian Klemt sold 15,000 shares of the company’s stock in a transaction on Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the completion of the sale, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at approximately $11,975,150. This represents a 6.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jack Kaye sold 38,810 shares of the stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $30.34, for a total value of $1,177,495.40. Following the completion of the sale, the director owned 20,439 shares of the company’s stock, valued at approximately $620,119.26. This trade represents a 65.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 314,560 shares of company stock worth $12,362,568 over the last 90 days. Corporate insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Private Trust Co. NA bought a new stake in shares of uniQure in the 3rd quarter worth about $28,000. Jones Financial Companies Lllp grew its stake in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares in the last quarter. CIBC Private Wealth Group LLC bought a new stake in uniQure in the third quarter valued at about $50,000. Main Management ETF Advisors LLC raised its stake in uniQure by 1.6% during the second quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock valued at $786,000 after buying an additional 912 shares in the last quarter. Finally, Knott David M Jr acquired a new stake in uniQure during the third quarter valued at approximately $117,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Down 0.5%

uniQure stock opened at $27.49 on Friday. The stock’s 50 day moving average price is $45.78 and its 200 day moving average price is $25.81. uniQure has a 1-year low of $5.89 and a 1-year high of $71.50. The company has a market cap of $1.71 billion, a PE ratio of -7.01 and a beta of 0.59. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, sell-side analysts predict that uniQure will post -3.75 EPS for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.